Agile Therapeutics Reveals Final Delisting Notice From Nasdaq
Portfolio Pulse from Benzinga Newsdesk
Agile Therapeutics has received a final delisting notice from Nasdaq, with its common stock to be suspended from trading on March 26, 2024. Post-delisting, the stock will be available for trading on the OTC Market.
March 25, 2024 | 8:31 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Agile Therapeutics will be delisted from Nasdaq and move to OTC Market trading on March 26, 2024.
Delisting from a major exchange like Nasdaq generally reflects negatively on a company's financial health and compliance with exchange requirements. This move to the OTC Market could lead to reduced visibility, liquidity, and investor confidence in AGRX, potentially driving the stock price down in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100